RevealDx, a leader in the characterization of lung nodules, announces MDR Certification of RevealAI-Lung.
The RevealDX product, RevealAI-Lung, characterizes nodules by producing a score called the Malignancy Similarity Index (mSI™) to assist Radiologists with the creation of follow-up recommendations. The company has validated the software on over 1,500 patients from a variety of cohorts. RevealAI-Lung is the first device with claims for lung nodules that certifies it reduces time to diagnosis and reduces false positives.
Related: Aqua Medical wins FDA IDE to launch trial for ablation procedure that treats diabetes
“Our technology is augmentative, not just assistive, uncovering radiomic biomarkers invisible to the human eye. RevealAI-Lung’s mSI™ score adds significant value to the Radiologist as they determine the best follow up recommendation for the patient,” said Chris Wood, CEO of RevealDx. “The technology has the potential to identify up to 45% of malignant nodules when they first appear, instead of waiting for an interval scan. As part of a comprehensive nodule management program, that could translate to thousands of lives saved each year.”
This announcement comes alongside Lung Cancer Awareness Month, taking place in November to raise public knowledge about the disease and encourage early detection and prevention. As a part of the company’s commitment to advancing lung health, RevealDx will also be exhibiting at the RSNA Meeting in booth #5121 beginning November 30, 2025.
